CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 29, 2011
Result type: Reports
Project Number: SF0226-000
Product Line: Reimbursement Review

Generic Name: Aripiprazole

Brand Name: Abilify

Manufacturer: Bristol-Myers Squibb

Therapeutic Area: Schizophrenia and related psychotic disorders

Indications: Schizophrenia and Related Psychotic Disorders

Submission Type: Request For Advice

Project Status: Complete

Date Recommendation Issued: July 18, 2011

Recommendation Type: List with clinical criteria and/or conditions